Article
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
Cancer cell - 14 Aug 2023
de Miguel Fernando J, Gentile Claudia, Feng William W, Silva Shannon J, Sankar Akshay, Exposito Francisco, Cai Wesley L, Melnick Mary Ann, Robles-Oteiza Camila, Hinkley Madeline M, Tsai Jeanelle A, Hartley Antja-Voy, Wei Jin, Wurtz Anna, Li Fangyong, Toki Maria I, Rimm David L, Homer Robert, Wilen Craig B, Xiao Andrew Z, Qi Jun, Yan Qin, Nguyen Don X, Jänne Pasi A, Kadoch Cigall, Politi Katerina A
Abstract excerpt
Acquired resistance to tyrosine kinase inhibitors (TKI), such as osimertinib used to treat EGFR-mutant lung adenocarcinomas, limits long-term efficacy and is frequently caused by non-genetic mechanisms. Here, we define the chromatin accessibility and gene regulatory signatures of osimertinib sensitive and resistant EGFR-mutant cell and patient-derived models and uncover a role for mammalian SWI/SNF chromatin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.